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Background: The asthma managing strategy has evolved and inhaled corticosteroids
(ICS) are now the cornerstone of asthma treatment. Their effect on symptoms and
exacerbations are well ascertained, whereas their effects on asthma mortality are
still matter of debate. This ecological study evaluated asthma mortality rates and
drug sales in the decade 1990–1999 in Argentina.
Methods: Mortality (overall and adjusted for 5–34 years) was obtained from the
Argentinean Epidemiological Institute, and data on the sales of antiasthma drugs
were provided by the International Marketing Survey.
Results: There was a significant change in drug sales in the spanned period: ICS
+479%, inhaled b2 agonists +32%, theophylline 63%. The crude and adjusted
mortality rates were 3.38 and 0.72 in the 1980–1989 decade, and 2.58 (Po0:05) and
0.38 (Po0:01) in the subsequent one. There was inverse correlation between inhaled
corticosteroid sale and age-adjusted (5–34) asthma mortality (r ¼ 0:84;
P ¼ 0:003), and the same with global mortality rates (r ¼ 0:81; P ¼ 0:005). A
positive correlation was also seen between theophylline sales and mortality.
Conclusion: The increased sale of ICS and possibly the decrease of theophylline use
seem to be the more relevant factors associated with decreased asthma mortality in
Argentina.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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About 20 years ago, articles began to appear in
literature suggesting that inhaled corticosteroids
(ICS) would represent a significant advance in
asthma therapy with respect, for instance, to
theophylline.1 Nowadays, the literature supporting
the efficacy and effectiveness of ICS is outstanding,
and these drugs are unanimously regarded as the
cornerstone of the long-term management of
asthma.2
The rationale for using ICS stands in the
pathogenesis of asthma that is a chronic inflamma-
tory disease of the lower airways, where numerous
cell types are involved, including lymphocytes,
eosinophils, and mast-cells.3 ICSs have a wide
spectrum of actions on inflammatory cells and
mediators,4 which have been largely demonstra-
ted in vitro. These actions result, in vivo, in improved
symptoms and pulmonary function, decreased
need for bronchodilators, reduction of exacerbations
and improved quality of life. At the beginning of the
1990s it become clear that, beyond the usually
measured clinical parameters, the regular use of ICS
was associated with a reduction of hospitalizations
and of the risk of fatal asthma.5 These earliest
observations were subsequently replicated in other
large-population-based surveys, but the real effect of
ICS on asthma mortality is still matter of debate,6 and
also other changes in therapeutic patterns may
account for epidemiological changes.
In Argentina, asthma mortality rate was pre-
viously shown to be high.7,8 Some asthma education
for physicians and health-care providers was
delivered by specialists since the late 1980s, but
starting from 1996 a broad, systematic, and
intensive educational program based on GINA
guidelines was implemented. This programme
focused the therapeutic recommendations in order
to achieve a better asthma control and a potential
decrease in asthma mortality rates.9 In the present
retrospective ecological study we attempted to
determine whether a correlation could be found
between the changes in antiasthma medication
prescriptions, in particular ICS use, and asthma
mortality rates in Argentina, by examining the
1990–1999 decade, for which complete sets of data
were available.Methods
Mortality data were provided by National Epide-
miological Institute. Data concerning the sales of
antiasthmatic drugs were provided by the Interna-tional Marketing Survey (IMS). Antiasthma drugs
were subdivided into seven major categories:
xanthines (theophylline and allied drugs), inhaled
and oral b2 agonists, inhaled cromones, antic-
holinergics, oral steroids and ICS. Of note, combi-
nation therapy (ICS+B2) includes only
beclometasone+salbutamol, since the other asso-
ciations of drugs were marketed in Argentina only
after 1999. Demographic data concerning the
general population were obtained from the Na-
tional Institute of Statistics and Census, and
mortality data were provided by the National
Epidemiological Institute ‘‘E.Coni’’. The statistical
analysis was performed applying the w2-test.
Correlations between asthma mortality and drug
sales were evaluated by the Spearman’s rho
coefficient. A SASTM statistical package was used
to entry and process the data.Results
Argentina has a population of about 36,260,000
inhabitants. The average annual income per person
in 1999 was about 8547 USD. In the same year, the
total expenditure for health care was 24,840
million USD, distributed as follows: 23.52% public
effectors, 34.08% social security, and 42.40 private
sector.
The prevalence of asthma in Argentina, accord-
ing to the ISAAC data obtained in Buenos Aires,
Rosario and Cordoba ranged from 15.4% at the age
of 6–7 years to 11.2% at the age of 13–14 years.10
The asthma mortality crude rate and the rate
adjusted for the age 5–34 years in Argentina were
3.38 and 0.72, respectively, in the 1980–1989
decade. Those values decreased to 2.58 (Po0:05)
and 0.38 (Po0:01), respectively, in the 1990–1999
period. Thus there was a clear-cut decrease in the
overall mortality rate in the space of two decades.
Looking more into detail, during the 1990–1999
decade, asthma mortality rates showed a gradual
decreasing trend, that become apparent starting
from 1992, reaching the value of 1.76 and 0.20
(adjusted rate) in 1997.11
Concerning drug market (Table 1), in 1990 b2
agonists represented 33.79% of total anti-asthmatic
drugs sale, followed by xanthines (30.3%) and oral
b2 agonists (16.6%). Cromones (1.23%), systemic
steroids (2.28%) and ICS (1.94%) accounted for
about 5% of sales. Interestingly, around 8% of the
market of antiasthmatic drugs was still represented
by ketotifen. In 1999 the proportions had greatly
changed (Table 1): ketotifen decreased to 3.98%,
and oral b2 agonists decreased to 6.1%, as well as
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Table 1 Percentages of sales in the market of antiasthmatic drugs.
Drug class 1990 1999 % Change P (w2)
Inhaled b2 agonists 33.79 44.70 +32 NS
Xanthines 30.30 11.91 61b 0.02
Oral b2 agonists 16.60 6.12 63 0.02
ICS 1.94 11.25 +479 o 0.001
Systemic steroids 2.28 1.02 56 NS
Cromones 1.23 0.8 34 NS
Ketotifen 8.57 3.98 54 NS
ICS+b2 — 10.22 — NA
Anticholinergics 5.29 10 +89 0.02
100 100
Figure 1 Global trend for the sales of theophylline,
inhaled bronchodilators and ICS in the decade 1990–1999.
Figure 2 Ratio between sold inhaled b2 agonists and ICS.
Figure 3 Sales of ICS before and after the introduction of
the GINA guidelines in Argentina.
Figure 4 Relationship between ICS sales, global mortal-
ity and adjusted mortality.
Asthma mortality and drug sales in Argentina 1433xanthines that fell to 11.9% of the market. On the
contrary, inhaled steroids raised in 1999 to 11.5% of
the market of antiasthmatic drugs. The most
important differences in sales between 1990 and
1999 were therefore seen for xanthines, oral b2
agonists, and inhaled steroids. There was also an
increase of inhaled b2 agonists.
The paradigmatic behavior of the sales through-
out the decade is outlined in Fig. 1 for theophyl-
line, ICS, and inhaled b2 agonists. Of note, there
was a significant change in the ratio between sold
b2 agonists and ICS (Fig. 2). Moreover, there was asignificant difference in ICS cumulative sales before
VS after the introduction of the GINA educational
program in Argentina in 1996 (Fig. 3). As shown in
Fig. 4, there was an inverse correlation between
ICS sale and age-adjusted (5–34) asthma mortality
(r ¼ 0:84; P ¼ 0:003), and the same occurred with
global mortality rates (r ¼ 0:81; P ¼ 0:005). The
correlation was also significant for xanthines
ARTICLE IN PRESS
H. Neffen et al.1434(P ¼ 0:002 and 0:03). An inverse correlation was
present between inhaled b2 agonists sales and
overall asthma mortality (P ¼ 0:01), but this
correlation disappeared when the adjusted (5–34)
mortality rate was considered.Discussion
ICS have, in the last 20 years, deeply changed the
general strategy of asthma management, and
currently represent the basis for the therapy of
every form and severity of asthma. Beyond the
functional and clinical effects that can be imme-
diately demonstrated in clinical trials, ICS exert
also a relevant population impact, namely reduc-
tion of hospitalizations and of exacerbations. These
effects have been examined in several large
studies, with different designs, such as cohort,12–15
case-control,16,17 and ecologic studies.18,19 The
effect of ICS on asthma mortality rates is less clear
and more difficult to assess, because mortality for
asthma is a less frequent event, and largely varies
across countries, ranging from about 0.5 to 4.0 per
100,000 patients.20 There are ecologic and cohort
studies on this problem with positive results.18,21–23
Of note, in the recent study by Suissa and Ernst18 a
positive effect on asthma mortality rates was
described not only with ICS but also with leuko-
triene antagonists. On the other hand, also incon-
clusive data were reported.24,25 Due to the low
frequency of the event, reliable answers can be
obtained only by spanning long periods and exam-
ining very large populations, such as can be done in
ecologic studies.
Ecologic studies are a particular kind of epide-
miologic surveys that attempt to correlate secular
trends in morbidity or mortality of a given disease
with the corresponding trends in the use (or sale) of
medications for that disease. This type of investi-
gation has intrinsic limits, since no information is
provided on the individual exposure to the drug or
about the individual confounding factors.6 In addi-
tion, the ecologic methodology does not allow to
formally define a causative association between
drugs and outcome. Nevertheless, the power of this
design stands in the amplitude of the population
observed and in the long period spanned.
Our results clearly evidenced a decrease in
asthma mortality associated to the changes in
overall therapeutic strategy. In particular, in-
creased sales of ICS and decreased sales of
xanthines seemed to be the most influential factors
associated with asthma mortality rates. The in-
creased use of ICS has been previously shown toinversely correlate with mortality,21,23,26 whereas
the relative effect of the reduced use of xanthines
is more difficult to evaluate. Indeed, there are
some reports highlighting the increased risk of
asthma death by xanthines,27,28 but no large
ecological study. We also found an inverse correla-
tion between the sale of inhaled b2 agonists and
overall mortality rate, but this correlation was no
more present for the adjusted mortality rate.
Moreover, it has been recently shown that an
excess in the use of short acting b2 agonists may
be even associated to increased risk of death.29 Of
note, this is the first ecological study performed in
Latin America showing the association between
changing prescriptions and asthma mortality, and
evidencing the role of educational programs. The
results of our survey confirm a previous Argentinian
questionnaire-based report, indicating that the
attitude of physicians towards asthma diagnosis
and management was slowly changing.30 Finally,
for the first time, a trend correlation between
the use of xanthines and asthma mortality was
documented.
It could be hypothesized that the decrease in
asthma mortality in Argentina, are due to an
improved performance of the healthcare system,
with a better access to healthcare providers.
However, when comparing the percentage of
patients without medical insurance in 1991 and
1999 it can be see that they increased from 28% to
35%, in relation to the increased unemployment
rate. Thus, that factor can be reasonably excluded.
Finally, it can be supposed that chronic obstructive
pulmonary disease (COPD) is a confounding factor
for the use of ICS, but we found that in Argentina in
the considered decade, prescriptions of ICS for
COPD were less than 10% according to the audit of
prescriptions.
In conclusion, there has been a significant change
in therapeutic strategy for asthma in the consid-
ered decade, and this change was associated to a
clear-cut decrease in asthma mortality. This maybe
attributed mainly to the increased use of inhaled
corticosteroids. Moreover, it is likely that the
introduction and dissemination of Global Initiative
for Asthma (GINA) guidelines has reinforced the
attitude towards more appropriate prescriptions
for asthma in Argentina.
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